This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MAFA | |
|---|---|
| Name | MAFA |
| Uniprot | Q9D2D0 |
| Organism | Mus musculus; Homo sapiens |
| Chromosomal location | human 8q24.3 |
| Length | ~373 aa (human) |
| Family | Large MAF transcription factors |
MAFA
MAFA is a member of the large MAF family of basic leucine zipper (bZIP) transcription factors with critical roles in pancreatic beta cell identity and function, ocular development, and neuronal differentiation. First characterized through studies in rodent pancreatic islets and retinal tissue, MAFA interacts with multiple lineage-defining regulators and signal transduction pathways to drive cell-type specific transcriptional programs. Mutations, dysregulation, or altered post-translational modification of MAFA have been linked to monogenic diabetes, insulinomatosis, age-related beta cell decline, and ocular phenotypes, making it a focus of research spanning endocrinology, developmental biology, and translational medicine.
MAFA belongs to the leucine zipper family of transcription factors related to the v-MAF oncogene and is paralogous with MAFB and c-MAF. Early functional characterization used models and systems including Mus musculus, Rattus norvegicus, and human islet preparations, revealing conserved roles in insulin gene regulation and glucose-responsive transcription. Research groups across institutions such as Harvard University, University of Cambridge, Max Planck Institute, and the National Institutes of Health have delineated MAFA’s importance in pancreatic development, while clinical genetics consortia have identified pathogenic human variants.
The MAFA protein contains an N-terminal transactivation domain, an acidic region, and a conserved basic region–leucine zipper (bZIP) motif mediating DNA binding and dimerization with partners such as c-JUN and FOS family members. The human MAFA gene maps to chromosome 8q24.3 and is encoded by multiple exons; orthologs are present in mammalian genomes and conserved motifs are noted in vertebrate orthologs from Danio rerio to Mus musculus. Structural studies using techniques from groups at European Molecular Biology Laboratory and Stanford University have characterized the bZIP–DNA interface and phosphorylation sites that modulate transactivation. MAFA forms homodimers and heterodimers with large MAF family members and interacts with co-regulators including members of the PDX1 and NKX family.
MAFA expression is highly enriched in pancreatic beta cells, with additional expression in subsets of retinal cells and certain neuronal populations. Developmental and adult expression profiles, defined by single-cell RNA sequencing datasets from consortia including the Human Cell Atlas and laboratories at Broad Institute, show dynamic MAFA induction during beta cell maturation and modulation by metabolic cues such as glucose and oxidative stress. Transcriptional regulation involves enhancers bound by pancreatic lineage transcription factors like PDX1, NEUROD1, and NKX6-1; signaling pathways including the insulin/IGF axis, MAPK, and GSK3-mediated phosphorylation influence MAFA stability. Post-translational control by ubiquitin ligases and phosphorylation at defined serine/threonine residues determines nuclear localization and proteasomal turnover, as demonstrated in studies from University of California, San Francisco and University of Tokyo.
In pancreatic beta cells, MAFA directly activates the insulin (INS) promoter and genes required for glucose sensing and insulin secretion such as GLUT2 homologs and enzymes of glycolysis, thereby sustaining glucose-stimulated insulin secretion. MAFA cooperates with PDX1 and NKX6-1 to establish mature beta cell transcriptional identity and repress disallowed genes. In the retina and central nervous system, MAFA-related transcriptional programs contribute to differentiation and survival of specific neuronal subtypes; developmental studies involving Zebrafish and mammalian retina models have elucidated MAFA-dependent gene networks. MAFA also participates in adaptive responses to metabolic stress by regulating antioxidative genes and endoplasmic reticulum homeostasis.
Heterozygous missense mutations in MAFA have been associated with familial insulinomatosis and diabetes mellitus through dominant effects on protein stability, leading to either hyperinsulinemic hypoglycemia or diabetes depending on mutation and sex, as reported in cohorts assembled by clinical genetics centers including Mayo Clinic and Great Ormond Street Hospital. Reduced MAFA expression or activity is implicated in beta cell dysfunction in type 2 diabetes cohorts analyzed by consortia such as Accelerating Medicines Partnership and population studies at Johns Hopkins University. In oncology, dysregulated large MAF proteins are established oncogenic drivers in multiple myeloma and other malignancies; while MAFA is less commonly oncogenic, its paralogs and fusion events characterized by groups at Dana-Farber Cancer Institute contextualize potential pathogenic mechanisms.
Knockout and conditional deletion models in Mus musculus have demonstrated that loss of MAFA impairs glucose-stimulated insulin secretion and accelerates beta cell dedifferentiation, with double knockouts with MAFB revealing redundant and nonredundant functions. Transgenic overexpression and knockin mice carrying human pathogenic variants recapitulate aspects of insulinomatosis and diabetes phenotypes, informing mechanisms of age-dependent penetrance observed in human pedigrees studied at Imperial College London and University of Oxford. In vitro functional studies use human induced pluripotent stem cell-derived beta-like cells, rodent islets, and CRISPR-engineered cell lines developed at centers including MIT and ETH Zurich to dissect transcriptional networks and post-translational regulation.
MAFA status informs precision diagnostics for monogenic forms of hypoglycemia and diabetes in genetic testing programs at institutions such as Genomics England and clinical endocrinology services. Therapeutic strategies aim to restore MAFA function or stabilize protein levels via modulation of upstream kinases, proteostasis pathways, or through gene therapy and beta cell replacement approaches being explored by companies and academic translational centers including Cambridge Biomedical Campus and Stanford Medicine. Understanding MAFA’s interactions with PDX1 and other lineage factors also guides efforts in cell reprogramming for regenerative medicine and for improving function of transplanted islets.
Category:Transcription factors Category:Pancreatic beta cell biology Category:Endocrinology